Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jul 1;109(7):2297-2302.
doi: 10.3324/haematol.2023.284109.

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Emilio Iannitto  1 , Simone Ferrero  2 , Côme Bommier  3 , Daniela Drandi  2 , Martina Ferrante  2 , Krimo Bouabdallah  4 , Sylvain Carras  5 , Guido Gini  6 , Vincent Camus  7 , Salvatrice Mancuso  8 , Luigi Marcheselli  9 , Angela Ferrari  10 , Michele Merli  11 , Benoit Tessoulin  12 , Caterina Stelitano  13 , Kheira Beldjord  14 , Giovanni Roti  15 , Fabrice Jardin  6 , Barbara Castagnari  16 , Francesca Palombi  17 , Lucile Baseggio  18 , Alexandra Traverse-Glehen  19 , Claudio Tripodo  20 , Anna Marina Liberati  21 , Margherita Parolini  22 , Sara Usai  23 , Caterina Patti  24 , Massimo Federico  25 , Maurizio Musso  26 , Marco Ladetto  27 , Emanuele Zucca  28 , Catherine Thieblemont  3
Affiliations
Clinical Trial

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Emilio Iannitto et al. Haematologica. .

Erratum in

No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Progression-free survival and overall survival at 5 years with a median observation time of 69 months. (A) Progression-free survival (PFS). (B) Overall survival (OS). CI: confidence interval.
Figure 2.
Figure 2.
Clinical response and undetectable minimal residual disease rate at different time points. (A) Individual minimal residual disease (MRD) status, clinical response, and outcome at different times. (B) Undetectable MRD rate at different time points. ER: early restaging at 4 months; EOT: end of treatment at 6 months; FU-1: 1-year follow-up; FU2: 2-year follow-up; Last-FU: last available control. Red dot: MRD+ (at least 1 MRD-positive sample, either bone marrow [BM] or peripheral blood [PB]); blue spot: MRD- (unmeasurable MRD); black dot: dead; CR: complete remission; PR: partial remission; SD: stable disease; R: relapse; P: progression; green arrow: alive at last FU.
Figure 3.
Figure 3.
Landmark progression-free survival analysis stratified by minimal residual disease evaluated at different time points. (A) Overall minimal residual disease (MRD) at early restaging after 3 bendamustine rituximab courses (ER). (B) Overall MRD at end of treatment (EOT). (C) Overall MRD at 1-year follow-up (FU-1). (D) Peripheral blood MRD at ER. PFS: progression-free survival; overall MRD: at least 1 MRD-positive sample (either bone marrow or peripheral blood); MRD-: unmeasurable MRD.
See this image and copyright information in PMC

References

    1. Piris MA, Isaacson PG, Swerdlow SH, et al Splenic marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: IARC Press; 2017. p. 223-225.
    1. Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016;127(17):2072-2081. - PubMed
    1. Kalashnikov I, Tanskanen T, Viisanen L, et al. . Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study. Blood Cancer J. 2023:13(62):1-8. - PMC - PubMed
    1. Luminari S, Merli M, Rattotti S, et al. . Brief report early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 Study. Blood. 2019;134(10):798-801. - PubMed
    1. Zucca E, Arcaini L, Buske C, et al. . Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17-29. - PubMed

Publication types

MeSH terms